Dosage patents: Down the hatch

The Supreme Court judgment on March 27, 2019 in Actavis v ICOS UK concerned ICOS’s EP (UK) 1 173 181, exclusively licensed to Eli Lilly, and found it invalid for lack of inventive step in the face of Actavis’, and others’, revocation challenge.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Merck KGaA agrees $11.3bn deal in major life sciences expansion

26 June 2026 Deal is aimed at strengthening German company’s presence across high-growth life sciences markets by adding a portfolio of advanced research and analytical technologies.

Biotechnology

Novartis and Eli Lilly sign separate $1.9bn novel drug deals

25 June 2026 Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines.

Biotechnology

Insilico lands potential $2.5bn AI biotech partnership

22 June 2026 The partnership, announced at BIO 2026, marks the largest Asia-Pacific partnership by potential value that the AI-driven drug discovery company has secured to date.

More features

LSD trade secrets suit over clinical trail info thrown out by judge

HGF expands European offering with pair of in-house hires

Ashurst Perkins Coie opens its doors following landmark merger

Merck KGaA agrees $11.3bn deal in major life sciences expansion

Novartis and Eli Lilly sign separate $1.9bn novel drug deals

Novo secures website blocking to tackle fake weight-loss drugs

Insilico lands potential $2.5bn AI biotech partnership

UPC hands Occlutech second win against Chinese medtech company in a month

Dosage patents: Down the hatch

More on this story

Editor's picks

Editor's picks

More features